Table 3 Multidrug resistance in in vitro models.

From: The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review

Model

Treatment

RI

Drugs tested for cross-resistance

ABCB1/PGP overexpression

Reference

   

No cross-

Cross-resistance

  
   

resistance

   

Serra_U2OS/MTX-C

MTX

135

DOX

TRIM

Y

[34, 37]

Mukherjee_HOS/CDDP-P

CDDP

2.2

–

5-FU

Y

[41]

Partial MAP resistance

Serra_U2OS/DOX-C

DOX

330

–

MTX

Y

[34]

Serra_SAOS2/DOX-C

DOX

338

–

MTX

Y

[34]

Shen_U2OS/DOX-P

DOX

95.6

–

CDDP, PAC

Y

[44]

Shen_MG63/DOX-P

DOX

72.9

–

CDDP, PAC

Y

[44]

Wang_SAOS2/MTX-P

MTX

12.73

CDDP

DOX, IFOS, EPI, THP

N

[49]

Complete MAP resistance

Serra_SAOS2/MTX-C

MTX

281

–

DOX, CDDP, TRIM

Y

[34, 37]

Lourda_U2OS/DOX-C

DOX

15

–

MTX, CDDP

Y

[72]

Lourda_KHOS/DOX-C

DOX

6.3

–

MTX, CDDP

Y

[72]

Han_SOSP9607/CDDP-P

CDDP

6.25

PAC

MTX, DOX

N

[54]

Wang_MG63/DOX-C

DOX

10.53

–

MTX, CDDP, IFOS

Y

[58]

Xu_MG63/DOX-C

DOX

6

–

MTX, CDDP

NA

[65]

  1. Chemoresistant models were generated by exposure to a single MAP agent. Cross-resistance to further MAP drugs, in addition to non-MAP drugs such as (TRIM) Trimetrexate, (PAC) Paclitaxel, (THP) Theprubicin, (EPI) Epirubicin, (5-FU) 5-Fluorouracil, was also investigated in some studies. Models with partial MAP resistance were determined to be cross-resistant to one further MAP drug and include those that were not investigated for complete MAP resistance. Complete MAP resistance identifies models that were determined to be resistant to all MAP agents. Expression of ABCB1/PGP is indicated compared to the respective parental control. (–) No further drugs tested, NA Not tested.
Back to article page